{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-115672","form_type":"8-K","ticker":"ELAN","cik":"0001739104","company_name":"Elanco Animal Health Inc","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.934911+00:00","generated_at":"2026-06-22T04:09:02.144199+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Elanco Q3 revenue $1,028M, net loss $49M; cuts FY 2022 guidance on FX and macro headwinds","bullets":["Q3 revenue down 9% reported (4% constant currency) to $1,028M; pet health fell 11%, farm animal down 7%.","Reported EPS $(0.10); adjusted EPS $0.20 (up 5% YoY); adjusted EBITDA $205M (19.9% margin, +120bps).","FY 2022 revenue guidance lowered to $4,385-4,430M (from $4,465-4,550M); adjusted EPS cut to $1.01-1.07 from $1.06-1.13.","Net leverage ratio 5.2x; $170M gross debt reduction in Q3; cash flow from ops $189M vs $89M YoY.","Pipeline: FDA submission for broad-spectrum parasiticide; SGLT-2 feline diabetes drug and parvovirus mAb expected approvals by early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-115672","json":"https://secwatch.observer/filing/0001104659-22-115672.json","markdown":"https://secwatch.observer/filing/0001104659-22-115672.md","text":"https://secwatch.observer/filing/0001104659-22-115672.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739104/000110465922115672/0001104659-22-115672-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739104/000110465922115672/tm2229803d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:09:02.144199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e57f4b42f61e4325daafaaab2f736510f15da914","claim":"Elanco Animal Health Inc reported the fiscal quarter ended September 30, 2022 results: revenue $1,028 million, net income Reported Net Loss of $49 million, EPS Reported EPS of $(0.10). Guidance lowered.","evidence_excerpt":"Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Third Quarter 2022 Results • Third Quarter 2022 Financial Results ◦ Revenue of $1,028 million ◦ Reported Net Loss of $49 million, Adjusted Net Income of $96 million ◦ Adjusted EBITDA of $205 million or 19.9% of Revenue ◦ Reported EPS of $(0.10), Adjusted EPS of $0.20 ◦","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739104/000110465922115672/0001104659-22-115672-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended September 30, 2022"},{"label":"Revenue","value":"$1,028 million"},{"label":"Net income","value":"Reported Net Loss of $49 million"},{"label":"EPS","value":"Reported EPS of $(0.10)"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}